Average daily dose of AUSTEDO in clinical trials was >36 mg/day1,2

12 mg
18 mg
24 mg
30 mg
36 mg
42 mg
48 mg

Total Daily Dosage

 

More than half of patients were between 36 mg/day and 48 mg/day at the end of the long-term study2

Patients in the pivotal and long-term studies received the AUSTEDO BID formulation.1,2

Increase dose of once-daily AUSTEDO XR toward effective and tolerable symptom control1

Week 1:

12 mg

once daily

Week 2:

18 mg

once daily

Week 3:

24 mg

once daily

Week 4:

30 mg

once daily

 

Get started with 4-week Patient Titration Kit

 
4-week Patient Titration Kit

AND

Week 5:

36 mg

once daily

Week 6:

42 mg

once daily

Week 7:

48 mg

once daily

Q24 Q12
Q24 Q12 Q6
Q24 Q24

Continue titrating by 6 mg/day weekly1*

 

*48 mg/day maximum dose.1

Not actual image of 4-week Titration Kit.


Available in 6 mg, 12 mg, and 24 mg extended-release tablets1

Q6

6 mg

Q12

12 mg

Q24

24 mg

Tablets not shown at actual size.

AUSTEDO XR can be taken with or without food1

Swallow AUSTEDO® XR (deutetrabenazine) extended-release tablets whole. Do not chew, crush, or break tablets.1

AUSTEDO BID is also available

Dosing information for AUSTEDO XR and AUSTEDO BID1

 

Total Daily Dosage

AUSTEDO XR Strength/QTY

AUSTEDO BID Strength/QTY

Week 1

12 mg

12 mg QD (QTY 7)

6 mg BID (QTY 14)

Week 2

18 mg

12 mg QD (QTY 7)
+ 6 mg QD (QTY 7)

9 mg BID (QTY 14)

Week 3

24 mg

24 mg QD (QTY 7)

12 mg BID (QTY 14)

Week 4

30 mg

24 mg QD (QTY 7)
+ 6 mg QD (QTY 7)

9 mg BID (QTY 14)
+ 6 mg BID (QTY 14)

Week 5

36 mg

24 mg QD (QTY 7)
+ 12 mg QD (QTY 7)

Two 9 mg BID (QTY 28)

Week 6

42 mg

24 mg QD (QTY 7)
+ 12 mg QD (QTY 7)
+ 6 mg QD (QTY 7)

12 mg BID (QTY 14)
+ 9 mg BID (QTY 14)

Week 7

48 mg*

Two 24 mg QD
(QTY 14)

Two 12 mg BID
(QTY 28)

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999